Gilead new drug applications for twice-yearly Lenacapavir for HIV Prevention accepted by USFDA under priority review Ruchika Sharma19 Feb 2025 1:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...
Clinical trial reveals twice-yearly injection to be 96% effective in HIV prevention Dr. Kamal Kant Kohli4 Dec 2024 9:30 PM ISTFor oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every...
Gilead Sciences inks pacts with Dr Reddy's Labs, Emcure, Hetero and 3 others for HIV drug Lenacapavir Ruchika Sharma3 Oct 2024 7:15 PM ISTFoster City: Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical...
Medical Bulletin 09/ July/ 2024 Anshika Mishra9 July 2024 3:00 PM ISTHere are the top medical news for the day:Could Daily Sauna Sessions Prevent Menopausal Weight Gain? Study Sheds Light New research, presented at...
Clinical Trial Shows Injection Twice a Year 100% Effective in HIV Treatment Anshika Mishra9 July 2024 8:15 AM ISTLarge-scale clinical trials conducted in Uganda and South Africa have revealed a groundbreaking advancement in HIV prevention. The trials demonstrated...
Gilead Sciences bags USFDA nod for Sunlenca to treat HIV-1 infection Ruchika Sharma23 Dec 2022 4:09 PM ISTLenacapavir is a breakthrough innovation with the potential to be a preferred and versatile foundational long-acting agent due to its therapeutic...
Gilead Sciences bags European Commission nod for HIV drug Sunlenca Ruchika Sharma23 Aug 2022 1:30 PM ISTSunlenca is indicated in the European Union for the treatment of adults with multi-drug resistant HIV infection in combination with other...
Gilead Sciences Lenacapavir MAA gets EMA validation to treat HIV-1 Ruchika Sharma22 Aug 2021 10:00 AM ISTFoster City: Gilead Sciences, Inc. has recently announced that the company's Marketing Authorization Application (MAA) for lenacapavir, an...
Gilead Sciences, Merck collaborate to develop, commercialize Lenacapavir, Islatravir combo for HIV Ruchika Sharma17 March 2021 1:04 PM ISTFoster City & Kenilworth: Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, have recently announced that they...
